Clinical Trials
3 trialsNCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05117476 2025-11-24
MICA
Cullinan Therapeutics Inc.
Phase 1 Active not recruiting
NCT05772455 2024-10-28
A Study of XZB-0004 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1 Recruiting